Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376750 | 0.83 | IDO1 (0.35) | IDO1TDO2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4066340 | 0.80 | MIF (0.50) | MIFIDO1TDO2MEN1KMT2A | |
| SCHEMBL4066944 | 0.78 | MIF (0.36) | MIFIDO1TDO2ALDH1A1MAPK1 | |
| SCHEMBL14258119 | 0.78 | GBA1 (0.32) | IDO1TDO2ALDH1A1MAPK1 | |
| SCHEMBL3931566 | 0.75 | MIF (0.38) | MIFIDO1TDO2KMT2AALDH1A1 | |
| SCHEMBL8277843 | 0.75 | MIF (0.40) | MIFIDO1TDO2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4073072 | 0.73 | MAOB (0.42) | MIFIDO1TDO2 | |
| SCHEMBL3941261 | 0.72 | MIF (0.49) | MIFIDO1TDO2MEN1KMT2A | |
| SCHEMBL4072488 | 0.72 | MIF (0.36) | MIFIDO1TDO2ALDH1A1MAPK1 | |
| SCHEMBL13933061 | 0.72 | MAOA (0.40) | MIFMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506212-A | Amino-imidazolones and their use as medicaments for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| CN-101501041-A | Amino-imidazolones and their use as medicaments for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2035424-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035425-A1 | AMINO- IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145570-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007145570-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299087-A1 | New Compounds 319 | PSEN2, PSEN1, MAPT | MIF 3207/4885IDO1 4144/4885TDO2 4808/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | MIF 3256/4885IDO1 4221/4885TDO2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.